These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 33122010)

  • 21. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting the Changes in Oral Absorption of Weak Base Drugs Under Elevated Gastric pH Using an In Vitro-In Silico-In Vivo Approach: Case Examples-Dipyridamole, Prasugrel, and Nelfinavir.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2019 Jan; 108(1):584-591. PubMed ID: 30423339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.
    Hens B; Pathak SM; Mitra A; Patel N; Liu B; Patel S; Jamei M; Brouwers J; Augustijns P; Turner DB
    Mol Pharm; 2017 Dec; 14(12):4321-4333. PubMed ID: 28817288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vitro, in Silico, and in Vivo Assessments of Intestinal Precipitation and Its Impact on Bioavailability of a BCS Class 2 Basic Compound.
    Kou D; Zhang C; Yiu H; Ng T; Lubach JW; Janson M; Mao C; Durk M; Chinn L; Winter H; Wigman L; Yehl P
    Mol Pharm; 2018 Apr; 15(4):1607-1617. PubMed ID: 29522347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene.
    Kambayashi A; Dressman JB
    Eur J Pharm Biopharm; 2013 May; 84(1):200-7. PubMed ID: 23262163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A canine biorelevant dissolution method for predicting in vivo performance of orally administered sustained release matrix tablets.
    Walsh PL; Bothe JR; Bhardwaj S; Hu M; Nofsinger R; Xia B; Persak S; Pennington J; Bak A
    Drug Dev Ind Pharm; 2016; 42(5):836-44. PubMed ID: 26339722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In-vitro-in-silico investigation of the negative food effect of zolpidem when administered as immediate-release tablets.
    Paraiso RLM; Watanabe A; Andreas CJ; Turner D; Zane P; Dressman J
    J Pharm Pharmacol; 2019 Nov; 71(11):1663-1676. PubMed ID: 31566757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On the usefulness of four in vitro methods in assessing the intraluminal performance of poorly soluble, ionisable compounds in the fasted state.
    O'Dwyer PJ; Box KJ; Imanidis G; Vertzoni M; Reppas C
    Eur J Pharm Sci; 2022 Jan; 168():106034. PubMed ID: 34628003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of food effect on the oral absorption of clarithromycin from immediate release tablet using physiological modelling.
    Radwan A; Jayyousi R; Shraim N; Zaid AN
    Biopharm Drug Dispos; 2019 Apr; 40(3-4):121-134. PubMed ID: 30891805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
    Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
    Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biorelevant Two-Stage In Vitro Testing for rDCS Classification and in PBPK Modeling-Case Example Ritonavir.
    Fiolka T; Van Den Abeele J; Augustijns P; Arora S; Dressman J
    J Pharm Sci; 2020 Aug; 109(8):2512-2526. PubMed ID: 32387425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption.
    Willmann S; Edginton AN; Kleine-Besten M; Jantratid E; Thelen K; Dressman JB
    J Pharm Pharmacol; 2009 Jul; 61(7):891-9. PubMed ID: 19589231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs.
    Georgaka D; Butler J; Kesisoglou F; Reppas C; Vertzoni M
    Mol Pharm; 2017 Dec; 14(12):4181-4191. PubMed ID: 28366005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel in vivo predictive dissolution testing coupled with a modeling and simulation for hydrogel matrix monolithic extended release oral dosage forms.
    Kambayashi A; Dressman JB
    Eur J Pharm Sci; 2019 Oct; 138():105044. PubMed ID: 31421255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring clinically relevant dissolution specifications for oral solid dosage forms of weak acid drugs using an in silico modeling and simulation approach.
    Kambayashi A; Yomota C
    Eur J Pharm Sci; 2021 Apr; 159():105728. PubMed ID: 33484814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the physiological variability of fasted gastric pH and tablet retention time on the variability of in vitro dissolution and simulated plasma profiles.
    Kovačič NN; Pišlar M; Ilić I; Mrhar A; Bogataj M
    Int J Pharm; 2014 Oct; 473(1-2):552-9. PubMed ID: 25064726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Establishing the Safe Space via Physiologically Based Biopharmaceutics Modeling. Case Study: Fevipiprant/QAW039.
    Kourentas A; Gajewska M; Lin W; Dhareshwar SS; Steib-Lauer C; Kulkarni S; Hirsch S; Heimbach T; Mueller-Zsigmondy M
    AAPS J; 2023 Feb; 25(1):25. PubMed ID: 36788163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.